Clinical Trial

Role of Early API in Accurately Differentiating Hepatocellular Carcinoma From Dysplastic Nodules in Cirrhotic Patients

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 23, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Liver cirrhosis is a common consequence of chronic liver disease, resulting from sustained hepatic injury due to various etiologies. Cirrhosis predisposes individuals to the development of hepatocellular carcinoma (HCC), the most prevalent primary malignancy of the liver. Among cirrhotic patients, distinguishing between hepatocellular carcinoma and dysplastic nodules is crucial for timely diagnosis, treatment planning, and prognostic assessment.
Trial Details
NCT Number NCT07080372
Lead Sponsor Superior University
Conditions Dysplastic Nodule
Enrollment 73 participants
Start Date 2025-03-17
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-07-23